Entera Bio logo

Entera BioNASDAQ: ENTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

28 June 2018

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$58.93 M
-44%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector
-24%vs. 3y high
91%vs. sector
595.27
-56%vs. 3y high
99%vs. sector

Price

regular market | 4 min ago
$1.60$0.00(0.00%)

Dividend

No data over the past 3 years
$42.00 K$40.00 K
$42.00 K-$3.02 M

Analysts recommendations

Institutional Ownership

ENTX Latest News

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com08 November 2024 Sentiment: NEUTRAL

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
globenewswire.com08 November 2024 Sentiment: POSITIVE

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
zacks.com26 September 2024 Sentiment: POSITIVE

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Entera Bio to Participate in Upcoming Investor and Scientific Conferences
globenewswire.com20 August 2024 Sentiment: POSITIVE

JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:

All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
zacks.com15 August 2024 Sentiment: POSITIVE

Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
globenewswire.com09 August 2024 Sentiment: POSITIVE

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks Investment Research26 April 2024 Sentiment: NEGATIVE

Entera Bio Ltd. (ENTX) closed at $1.98 on the most recent trading day, reflecting a 1% decrease from the previous closing price.

Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
Zacks Investment Research18 April 2024 Sentiment: POSITIVE

At the end of the most recent trading day, Entera Bio Ltd. (ENTX) closed at $2.24, reflecting a 0.9% increase from the previous day's closing price.

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Zacks Investment Research12 April 2024 Sentiment: POSITIVE

Here is the performance comparison of Entera Bio Ltd. (ENTX) and FibroGen (FGEN) relative to their sector year to date.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Zacks Investment Research09 April 2024 Sentiment: POSITIVE

In this article, we explore why purchasing Entera Bio (ENTX) stock at this time could be a wise decision.

What type of business is Entera Bio?

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

What sector is Entera Bio in?

Entera Bio is in the Healthcare sector

What industry is Entera Bio in?

Entera Bio is in the Biotechnology industry

What country is Entera Bio from?

Entera Bio is headquartered in Israel

When did Entera Bio go public?

Entera Bio initial public offering (IPO) was on 28 June 2018

What is Entera Bio website?

https://www.enterabio.com

Is Entera Bio in the S&P 500?

No, Entera Bio is not included in the S&P 500 index

Is Entera Bio in the NASDAQ 100?

No, Entera Bio is not included in the NASDAQ 100 index

Is Entera Bio in the Dow Jones?

No, Entera Bio is not included in the Dow Jones index

When was Entera Bio the previous earnings report?

No data

When does Entera Bio earnings report?

The next expected earnings date for Entera Bio is 07 March 2025